Authors:
G Volpe, JD Bernstock, L Peruzzotti-Jametti, S Pluchino
Journal name: 
J Neuroimmunol
Abstract: 
There exists an urgent need for effective treatments for those patients suffering from chronic/progressive multiple sclerosis (MS). Accordingly, it has become readily apparent that different classes of stem cell-based therapies must be explored at both the basic science and clinical levels. Herein, we provide an overview of the basic mechanisms underlying the pre-clinical benefits of exogenously delivered non-hematopoietic stem cells (nHSCs) in animal models of MS. Further, we highlight a number of early clinical trials in which nHSCs have been used to treat MS. Finally, we identify a series of challenges that must be met and ultimately overcome if such promising therapeutics are to be advanced from the bench to the bedside.
DOI: 
http://doi.org/10.1016/j.jneuroim.2016.12.005
E-pub date: 
15 Dec 2016